COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Jefferies Healthcare Conference

Collegium to Participate in Jefferies Healthcare Conference

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.

Details of the event are as follows:

Fireside Chat Date and Time: Thursday, June 8, 2023, at 12:30 p.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Christopher James, M.D.                                                                                       

Vice President, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications



EN
01/06/2023

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports First Quarter 2025 Financial Results and Highlights ...

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1’25 with Cash, Cash Equivale...

May 8, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report First Quarter 2025 Financial Results on May 8, 202...

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will...

April 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Con...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Real-World Data at PainConnect 2025, the American...

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h...

March 27, 2025 1 EN
Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 2 directors

Two Directors at Collegium Pharmaceutical Inc sold 28,410 shares at between 30.025USD and 30.027USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

COLL COLLEGIUM PHARMACEUTICAL INC.
03/24/25 March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch